{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010426","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.111029+00:00","generated_at":"2026-06-04T13:10:50.984497+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A","bullets":["Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.","Guidance clarifies regulatory requirements for planned Phase 2b trial design.","Phase 2a challenge study in UK ongoing; topline results expected H2 2024.","Preparations underway for inhaled CC-42344 Phase 1 study in Australia.","Inhaled formulation showed superior lung exposure and favorable safety in preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010426","json":"https://secwatch.observer/filing/0001493152-24-010426.json","markdown":"https://secwatch.observer/filing/0001493152-24-010426.md","text":"https://secwatch.observer/filing/0001493152-24-010426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224010426/0001493152-24-010426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224010426/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:10:50.984497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}